Global Muscle Relaxant Drugs Market, By Drug Class (Neuromuscular Blocking Agents, Skeletal Muscle Relaxants, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2029.
Muscle Relaxant Drugs Market Analysis and Size
The global muscle relaxant drugs market is expected to witness significant growth during the forecast period. Growing elderly populations globally who are more susceptible to musculoskeletal disorders is the primary factor driving the growth of the market. Muscle relaxants are powerful drugs; though, these can have serious side effects such as heart failure, sedation, and paralysis. In many patients, sedation is reported as the common adverse effect. Therefore, physicians generally advise against driving or operating heavy machinery after muscle relaxant administration. Sudden outbreak of the COVID-19 pandemic imposed stringent lockdown regulations globally, causing interruptions in import and export activities of global muscle relaxant drugs market.
Data Bridge Market Research analyses a growth rate in the global muscle relaxant drugs market in the forecast period 2022-2029. The expected CAGR of global muscle relaxant drugs market is tend to be around 5.2% in the mentioned forecast period. The market was valued at USD 5.94 million in 2021, and it would grow upto USD 8.91 million by 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Muscle Relaxant Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Neuromuscular Blocking Agents, Skeletal Muscle Relaxants, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (U.S.), Lilly (U.S.), Amgen Inc. (U.S.), Actelion Pharmaceuticals Ltd (Switzerland)
|
|
Market Opportunities
|
|
Market Definition
Muscle relaxants are a diverse group of medications used to relax or reduce tension in the muscle. Baclofen, methocarbamol, and tizanidine are some of the muscle relaxant drugs that work in the brain or spinal cord to block over-excited neuronal pathways. In contrast, other relaxants, such as dantrolene and botulinum toxin, act directly on the muscle. Muscle relaxants primarily treat two major conditions: spasticity caused by cerebral palsy, multiple sclerosis, and stroke. And, muscle spasms are characteristically temporary and is linked with conditions such as low back pain, tension headache, or fibromyalgia. This disease occurrence is rising and important diagnostic procedures and treatments will boost the growth of the market.
Global Muscle Relaxant Drugs Market Dynamics
Drivers
- Rising Prevalence of Musculoskeletal Issues
The rising prevalence of musculoskeletal problems and growing customer awareness of their treatment and management are boosting the growth of the market. Structurally distinct medications are the recent technologically improved muscle relaxants used to soothe the muscle spasms, discomfort, and hyperreflexia. This boosts the growth of the market.
- Major Developments by the Market Players
There are several developments done by major market players that are boosting the growth of the market. For instance, in September 2019, Ipsen Biopharmaceuticals received U.S. Food and Drug Administration approval of expanded use of Dysport (abobotulinumtoxinA) for injection to treat children two years of age and older having upper limb spasticity excluding spasticity caused by cerebral palsy. Thus, this leads to the market expansion.
Opportunities
- Growing Prevalence of Lower Back Pain
As per the records of the World Health Organization (WHO), the non-specific burden of lower back pain has augmented significantly worldwide which is projected at 60–70% in industrialized countries whereas one-year prevalence increased rate 15–45%, adult prevalence 5% per annum and mostly incidence of lower back pain has seen in above 35 age bracket people. Thus, this factor is demanding more drugs and as a result is increasing the growth of the market.
- Growing Elderly Population
Life expectancy is growing around the world, which has led to an increase in the aging population. This trend positively impacts the industry by increasing the incidence of the disease and creating per capita demand for its remedies. Thus, this population demands high use of demyelinating diseases therapeutics and in return creates more opportunities for the market growth.
Restraints/Challenges
- Adverse Side-Effects of Muscle Relaxants
There are severe side-effects associated with muscle relaxants such as tiredness, dizziness, dry mouth, depression which restrict the market growth.
- High Investment and Strict Regulatory Norms
The growth of the muscle relaxant drug market is restricted by factors such as strict regulatory requirements and the risks associated with muscle relaxants. Being a complex process, the use, separation, and development of raw materials for the development of pharmaceutical and biopharmaceutical drugs demands professional and qualified personnel. Thus, all these factors restricts the growth of the demand for muscle relaxant drugs.
This global muscle relaxant drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global muscle relaxant drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Muscle Relaxant Drugs Market
Musculoskeletal pain witnessed to be the commonest problem in routine medical practice. Most pain sources are associated with muscles or fascia becoming damaged, which then triggers pain. Though COVID-19 primarily affects the lungs and internal organs, musculoskeletal injury from this disease was visible due to marked elevation in creatine kinase and lactate dehydrogenase levels. Additionally, pain management during the COVID-19 pandemic demands attention because of difficulties in accessing hospitals for medical services such as physical therapy and rehabilitation. Thus, COVID-19 left a major impact on global muscle relaxant drugs market.
Global Muscle Relaxant Drugs Market Scope
The global muscle relaxant drugs market is segmented on the basis of drug class, route of administration, end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Neuromuscular Blocking Agents
- Skeletal Muscle Relaxants
- Others
Route of Administration
- Oral
- Parenteral
End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Muscle Relaxant Drugs Market Regional Analysis/Insights
The global muscle relaxant drugs market is analysed and market size insights and trends are provided by drug class, route of administration,end-user, distribution channel as referenced above.
The major countries covered in the global muscle relaxant drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is considered to have the highest lucrative growth in the forecast period due to the rise of surgical procedures performed annually and increased prevalence of spasticity as well as advanced healthcare facilities.
Asia-Pacific is dominating the market due to the increase government initiatives and rapidly aging population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Muscle Relaxant Drugs Market Share Analysis
The global muscle relaxant drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global muscle relaxant drugs market.
Key players operating in the global muscle relaxant drugs market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Merck & Co., Inc. (U.S.)
- Lilly (U.S.)
- Amgen Inc. (U.S.)
- Actelion Pharmaceuticals Ltd (Switzerland)
SKU-